Faeth Therapeutics is exploding higher as investors react to the company's announcement that it will participate in upcoming investor conferences throughout September. This positive sentiment is further bolstered by market attention surrounding the stock's status as a momentum play, which has helped push shares to a new 52-week high of $40.54. The biotech firm continues to see strong technical performance, currently trading 36.0% above its 50-day moving average.